Plasma protein profiling in a stage defined pancreatic cancer cohort – Implications for early diagnosis

Summary, in English

Pancreatic ductal adenocarcinoma (PDAC) is a disease where detection preceding clinical symptoms significantly increases the life expectancy of patients. In this study, a recombinant antibody microarray platform was used to analyze 213 Chinese plasma samples from PDAC patients and normal control (NC) individuals. The cohort was stratified according to disease stage, i.e. resectable disease (stage I/II), locally advanced (stage III) and metastatic disease (stage IV). Support vector machine analysis showed that all PDAC stages could be discriminated from controls and that the accuracy increased with disease progression, from stage I to IV. Patients with stage I/II PDAC could be discriminated from NC with high accuracy based on a plasma protein signature, indicating a possibility for early diagnosis and increased detection rate of surgically resectable tumors.

• Author: Anna Sandström Gerdtsson; Christer Wingren; Helena Persson; Payam Delfani; Malin Nordström; He Ren; Xin Wen; Ulrika Ringdahl; Carl A K Borrebaeck; Jihui Hao
• Department/s: Department of Immunotechnology; BioCARE: Biomarkers in Cancer Medicine improving Health Care, Education and Innovation
• Publishing year: 2016-10-01
• Language: English
• Pages: 1305-1316
• Publication/Series: Molecular Oncology
• Volume: 10
• Issue: 8
• Links: http://dx.doi.org/10.1016/j.molonc.2016.07.001
• Document type: Journal article
• Publisher: Elsevier
• Topic: Cancer and Oncology
• Keywords: Antibody microarrays; Biomarker signatures; Early detection; Pancreatic cancer; Recombinant antibodies
• Status: Published
• ISBN/ISSN/Other: ISSN: 1574-7891